Primary myelofibrosis
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Primary myelofibrosis is a condition characterised by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
Video picks for Genetic conditionsVideo library
Description
Primary myelofibrosis is a condition characterised by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anaemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.
Because blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain.
Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.
Inheritance patterns
The source lists the following possible inheritance patterns: Not inherited. More than one pattern can apply in different cases.
Related genes
Other names
Agnogenic myeloid metaplasia
Chronic idiopathic myelofibrosis
Idiopathic myelofibrosis
Myelofibrosis with myeloid metaplasia
Myeloid metaplasia
Patient picks for Genetic conditions

Allergies, blood and immune system
Myelofibrosis
Myelofibrosis is a condition affecting the bone marrow and its blood cell production.
by Dr Rachel Hudson, MRCGP

Digestive health
Primary sclerosing cholangitis
Primary sclerosing cholangitis is an uncommon condition affecting the bile ducts and liver. Inflammation and scarring of the bile ducts can lead to liver damage and cirrhosis - a condition where normal liver tissue is replaced by scar tissue (fibrosis). Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. The outlook for people with primary sclerosing cholangitis can be very variable.
by Dr Colin Tidy, MRCGP

Cancer
Primary bone cancer
Primary bone cancer occurs where a cancer originates in a bone. It is a rare type of cancer. There are several different types. Treatments which may be considered include surgery, chemotherapy and radiotherapy. The type of treatment used and the outlook depend on various factors including the type, site and stage of the cancer.
by Dr Rosalyn Adleman, MRCGP

Children's health
1 in 5 children starting primary school are not fully protected against serious illnesses
Around 1 in 5 children going back to school are not protected against several serious illnesses. Read here about why UK Health Security Agency (UKHSA) and NHS England urge you to check your child’s vaccination record and catch up on any missed jabs, and what illnesses the vaccinations protect against.
by Lawrence Higgins

Digestive health
Primary biliary cholangitis
Primary biliary cholangitis (PBC) is a condition that slowly damages the bile ducts in your liver, leading to liver damage and, sometimes, liver scarring (cirrhosis).
by Dr Hayley Willacy, FRCGP

Cancer
Primary liver cancer
In primary liver cancer the cancer starts in the liver. In secondary liver cancer, the cancer spreads from another part of the body to the liver. Primary liver cancer is uncommon in the UK but is common in other parts of the world. In the UK, most cases develop as a complication of scarring of the liver (cirrhosis). In general the outlook is poor. Surgery to remove the cancer is an option in a small number of cases and, if it is possible, gives the best chance of a cure.
by Dr Toni Hazell, FRCGP
Related patient information and medicines

Patient information leaflet
Myelofibrosis
Myelofibrosis is a condition affecting the bone marrow and its blood cell production. What is mye... Myelofibrosis belongs to a group of diseases called myeloproliferative disorders. Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. What causes myelofibrosis. Myelofibrosis which occurs.

Patient information leaflet
Chronic myeloid leukaemia
Chronic myeloid leukaemia (CML) is sometimes called chronic myelogenous leukaemia, chronic granulocytic leukaemia, or chronic myelocytic leukaemia. What is chronic myeloid leukaemia. In this phase there are more than 30% blast cells in the blood and bone marrow. Very rarely, CML develops into a condition called myelofibrosis. This means that the.

Patient information leaflet
Polycythaemia rubra vera
Polycythaemia rubra vera (PRV) is a myeloproliferative disorder, which means the bone marrow makes too many blood cells. Gout Myelofibrosis There is a chance that, after about 15 years, PRV can develop into a condition known as myelofibrosis. Dr Krishna Vakharia , 24th November 2023 The National Institute for Health and Care Excellence (NICE) has.

Patient information leaflet
Liver function tests
Alpha-1 antitrypsin Alpha-1 antitrypsin deficiency (a hormone involved in protecting liver and lung cells from injury). Clotting factors Blood clotting tests (particularly if there is a suspicion that your blood is not clotting well or you have severe liver disease). Enhanced liver fibrosis score (ELF) -this is a set of three tests that can.

Patient information leaflet
Jaundice
Alcoholic hepatitis. Autoimmune hepatitis. Inflammation caused by poisons or as a side-effect of some medicines. Cirrhosis Cirrhosis. This is a condition where normal liver tissue is replaced by scar tissue (fibrosis). It tends to progress slowly and often does not cause symptoms in its early stages. However, as the function of the liver gradually.

Patient information leaflet
Primary sclerosing cholangitis
Primary sclerosing cholangitis is an uncommon condition affecting the bile ducts and liver. Inflammation and scarring of the bile ducts can lead to liver damage and cirrhosis - a condition where normal liver tissue is replaced by scar tissue (fibrosis). Different treatments are available to control symptoms that may develop and also to manage any.
Further reading and references
- Primary myelofibrosis; MedlinePlus, National Library of Medicine.
- Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socie G, Bordessoule D, Le Bousse-Kerdiles MC, Vainchenker W, Giraudier S. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008 Aug;22(8):1557-66. doi: 10.1038/leu.2008.137. Epub 2008 Jun 5.
- Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007 Aug 1;110(3):986-93. doi: 10.1182/blood-2006-12-064626. Epub 2007 May 1.
- Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
- Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.
- Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.
- Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, Plo I, Bordessoule D, Chomienne C, Delannoy A, Devidas A, Gardembas-Pain M, Isnard F, Plumelle Y, Bernard O, Vainchenker W, Najman A, Bellanne-Chantelot C; French Group of Familial Myeloproliferative Disorders. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009 Aug 20;114(8):1628-32. doi: 10.1182/blood-2009-01-197525. Epub 2009 Jun 29.
- Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.
- Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005 Nov 20;23(33):8520-30. doi: 10.1200/JCO.2004.00.9316.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

